Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.

Pratt SE, Durland-Busbice S, Shepard RL, Donoho GP, Starling JJ, Wickremsinhe ER, Perkins EJ, Dantzig AH.

Mol Cancer Ther. 2013 Apr;12(4):481-90. doi: 10.1158/1535-7163.MCT-12-0654. Epub 2013 Jan 31.

2.

Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.

Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH.

Clin Cancer Res. 2013 Mar 1;19(5):1159-68. doi: 10.1158/1078-0432.CCR-12-1184. Epub 2013 Jan 16.

3.

Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.

Baker JA, Wickremsinhe ER, Li CH, Oluyedun OA, Dantzig AH, Hall SD, Qian YW, Ring BJ, Wrighton SA, Guo Y.

Drug Metab Dispos. 2013 Mar;41(3):541-5. doi: 10.1124/dmd.112.048769. Epub 2012 Dec 10.

PMID:
23230131
4.

Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.

Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, Uhlik M, Dantzig AH, Foster FS, Kerbel RS.

Mol Cancer Ther. 2012 Mar;11(3):680-9. doi: 10.1158/1535-7163.MCT-11-0659. Epub 2011 Dec 21.

5.

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR.

J Med Chem. 2009 Nov 26;52(22):6958-61. doi: 10.1021/jm901181h.

PMID:
19860433
6.

Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport.

Pratt S, Chen V, Perry WI 3rd, Starling JJ, Dantzig AH.

Eur J Pharm Sci. 2006 Apr;27(5):524-32. Epub 2005 Dec 5.

PMID:
16337112
7.

Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1).

Norman BH, Lander PA, Gruber JM, Kroin JS, Cohen JD, Jungheim LN, Starling JJ, Law KL, Self TD, Tabas LB, Williams DC, Paul DC, Dantzig AH.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5526-30. Epub 2005 Oct 3.

PMID:
16202586
8.

Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.

Bueno AB, Collado I, de Dios A, Domínguez C, Martín JA, Martín LM, Martínez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, Jiang H, Schoepp DD, Stratford RE, Tabas LB, Tizzano JP, Wright RA, Herin MF.

J Med Chem. 2005 Aug 11;48(16):5305-20.

PMID:
16078848
9.

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.

Perry WL 3rd, Shepard RL, Sampath J, Yaden B, Chin WW, Iversen PW, Jin S, Lesoon A, O'Brien KA, Peek VL, Rolfe M, Shyjan A, Tighe M, Williamson M, Krishnan V, Moore RE, Dantzig AH.

Cancer Res. 2005 Aug 1;65(15):6593-600.

10.

The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.

Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH.

Mol Cancer Ther. 2005 May;4(5):855-63.

11.

Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin.

Behrens I, Kamm W, Dantzig AH, Kissel T.

J Pharm Sci. 2004 Jul;93(7):1743-54.

PMID:
15176063
12.

Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters.

Dantzig AH, Shepard RL, Pratt SE, Tabas LB, Lander PA, Ma L, Paul DC, Williams DC, Peng SB, Slapak CA, Godinot N, Perry WL 3rd.

Biochem Pharmacol. 2004 Mar 15;67(6):1111-21.

PMID:
15006547
13.

Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells.

Sampath J, Long PR, Shepard RL, Xia X, Devanarayan V, Sandusky GE, Perry WL 3rd, Dantzig AH, Williamson M, Rolfe M, Moore RE.

Am J Pathol. 2003 Nov;163(5):1781-90.

14.

Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey.

Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, Perry WL 3rd.

Mol Cancer Ther. 2003 Mar;2(3):307-16.

15.

Considerations in the design and development of transport inhibitors as adjuncts to drug therapy.

Dantzig AH, de Alwis DP, Burgess M.

Adv Drug Deliv Rev. 2003 Jan 21;55(1):133-50. Review.

PMID:
12535578
16.

Characterization and application of a vinblastine-selected CACO-2 cell line for evaluation of p-glycoprotein.

Laska DA, Houchins JO, Pratt SE, Horn J, Xia X, Hanssen BR, Williams DC, Dantzig AH, Lindstrom T.

In Vitro Cell Dev Biol Anim. 2002 Jul-Aug;38(7):401-10.

PMID:
12534340
17.

Identification and characterization of the canine multidrug resistance-associated protein.

Ma L, Pratt SE, Cao J, Dantzig AH, Moore RE, Slapak CA.

Mol Cancer Ther. 2002 Dec;1(14):1335-42.

18.

Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

Shepard RL, Cao J, Starling JJ, Dantzig AH.

Int J Cancer. 2003 Jan 1;103(1):121-5.

20.

Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione.

Qian YM, Grant CE, Westlake CJ, Zhang DW, Lander PA, Shepard RL, Dantzig AH, Cole SP, Deeley RG.

J Biol Chem. 2002 Sep 20;277(38):35225-31. Epub 2002 Jul 22.

21.

Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays.

Sandusky GE, Mintze KS, Pratt SE, Dantzig AH.

Histopathology. 2002 Jul;41(1):65-74.

PMID:
12121239
22.

GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain.

Mao Q, Qiu W, Weigl KE, Lander PA, Tabas LB, Shepard RL, Dantzig AH, Deeley RG, Cole SP.

J Biol Chem. 2002 Aug 9;277(32):28690-9. Epub 2002 May 28.

23.

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):974-81.

PMID:
11961114
24.

Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):964-73.

PMID:
11961113
25.

Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1).

Norman BH, Gruber JM, Hollinshead SP, Wilson JW, Starling JJ, Law KL, Self TD, Tabas LB, Williams DC, Paul DC, Wagner MM, Dantzig AH.

Bioorg Med Chem Lett. 2002 Mar 25;12(6):883-6.

PMID:
11958985
26.

A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.

Hu Y, Stephen AG, Cao J, Tanzer LR, Slapak CA, Harrison SD, Devanarayan V, Dantzig AH, Starling JJ, Rome LH, Moore RE.

Int J Cancer. 2002 Jan 10;97(2):149-56.

27.

Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic.

Dantzig AH, Law KL, Cao J, Starling JJ.

Curr Med Chem. 2001 Jan;8(1):39-50. Review.

PMID:
11172691
28.

Evaluation of an in vitro coculture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources.

Scism JL, Laska DA, Horn JW, Gimple JL, Pratt SE, Shepard RL, Dantzig AH, Wrighton SA.

In Vitro Cell Dev Biol Anim. 1999 Nov-Dec;35(10):580-92.

PMID:
10614867
29.

Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.

Norman BH, Dantzig AH, Kroin JS, Law KL, Tabas LB, Shepard RL, Palkowitz AD, Hauser KL, Winter MA, Sluka JP, Starling JJ.

Bioorg Med Chem Lett. 1999 Dec 6;9(23):3381-6.

PMID:
10612603
30.

Intestinal peptide transport systems and oral drug availability.

Yang CY, Dantzig AH, Pidgeon C.

Pharm Res. 1999 Sep;16(9):1331-43. Review.

PMID:
10496647
31.

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA.

J Pharmacol Exp Ther. 1999 Aug;290(2):854-62.

PMID:
10411602
32.

Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.

Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH.

Biochem Pharmacol. 1998 Sep 15;56(6):719-27.

PMID:
9751076
33.
34.

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.

Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C, Gruber J, Elmquist WF, Dantzig AH.

Adv Enzyme Regul. 1997;37:335-47.

PMID:
9381979
35.

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ.

Cancer Res. 1996 Sep 15;56(18):4171-9.

37.

Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin.

Hu M, Zheng L, Chen J, Liu L, Zhu Y, Dantzig AH, Stratford RE Jr.

Pharm Res. 1995 Aug;12(8):1120-5.

PMID:
7494822
38.

IAM chromatography: an in vitro screen for predicting drug membrane permeability.

Pidgeon C, Ong S, Liu H, Qiu X, Pidgeon M, Dantzig AH, Munroe J, Hornback WJ, Kasher JS, Glunz L, et al.

J Med Chem. 1995 Feb 17;38(4):590-4.

PMID:
7861406
39.

Peptide transporter function and prolidase activities in Caco-2 cells: a lack of coordinated expression.

Hu M, Zheng L, Chen J, Liu L, Li Y, Dantzig AH, Stratford RE Jr.

J Drug Target. 1995;3(4):291-300.

PMID:
8821003
40.
41.
42.

Association of intestinal peptide transport with a protein related to the cadherin superfamily.

Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, Jenkins IL, Duckworth DC, Sportsman JR, Mackensen D, Rosteck PR Jr, et al.

Science. 1994 Apr 15;264(5157):430-3.

PMID:
8153632
43.
44.

Basolateral 3-O-methylglucose transport by cultured kidney (LLC-PK1) epithelial cells.

Mullin JM, Kofeldt LM, Russo LM, Hagee MM, Dantzig AH.

Am J Physiol. 1992 Mar;262(3 Pt 2):F480-7.

PMID:
1558165
45.

Studies on the mechanism of action of A80915A, a semi-naphthoquinone natural product, as an inhibitor of gastric (H(+)-K+)-ATPase.

Dantzig AH, Minor PL, Garrigus JL, Fukuda DS, Mynderse JS.

Biochem Pharmacol. 1991 Oct 24;42(10):2019-26.

PMID:
1683772
46.
47.

Carrier-mediated uptake of cephalexin in human intestinal cells.

Dantzig AH, Bergin L.

Biochem Biophys Res Commun. 1988 Sep 15;155(2):1082-7.

PMID:
3421959
48.

Isolation and characterization of a glycine transport mutant in an established mammalian cell line, CHO(PEOT/1).

Fairgrieve M, Mullin JM, Dantzig AH, Slayman CW, Adelberg EA.

Somat Cell Mol Genet. 1987 Sep;13(5):505-12.

PMID:
2443987
49.

Isolation of a Fusarium solani mutant reduced in cutinase activity and virulence.

Dantzig AH, Zuckerman SH, Andonov-Roland MM.

J Bacteriol. 1986 Nov;168(2):911-6.

50.

Isolation and characterization of a CHO amino acid transport mutant resistant to melphalan (L-phenylalanine mustard).

Dantzig AH, Fairgrieve M, Slayman CW, Adelberg EA.

Somat Cell Mol Genet. 1984 Mar;10(2):113-21.

PMID:
6584987

Supplemental Content

Loading ...
Support Center